36.29
-0.4873(-1.32%)
Currency In USD
| Previous Close | 36.78 |
| Open | 36.61 |
| Day High | 36.78 |
| Day Low | 35.72 |
| 52-Week High | 62.58 |
| 52-Week Low | 23.42 |
| Volume | 233,503 |
| Average Volume | 810,693 |
| Market Cap | 2.11B |
| PE | 3.21 |
| EPS | 11.29 |
| Moving Average 50 Days | 37.68 |
| Moving Average 200 Days | 35.12 |
| Change | -0.49 |
If you invested $1000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, it would be worth $393.63 as of September 15, 2025 at a share price of $36.293. Whereas If you bought $1000 worth of Agios Pharmaceuticals, Inc. (AGIO) shares 5 years ago, it would be worth $948.09 as of September 15, 2025 at a share price of $36.293.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
GlobeNewswire Inc.
Aug 04, 2025 8:01 PM GMT
First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage P
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
GlobeNewswire Inc.
Jul 14, 2025 11:00 AM GMT
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conf